Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study

Background: SARS-CoV-2 variant Beta (B.1.351) was designated as a Variant of Concern (VoC) after becoming the dominant strain in South Africa and spreading internationally. BNT162b2 showed lower levels of neutralizing antibodies against Beta than against other strains raising concerns about effectiv...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shepherd R. Singer, M.D., Frederick J. Angulo, Ph.D., David L. Swerdlow, M.D., John M. McLaughlin, Ph.D., Itay Hazan, M.Sc., Netanel Ginish, B.S, Emilia Anis, M.D., Ella Mendelson, Ph.D., Orna Mor, Ph.D., Neta S Zuckerman, Ph.D., Oran Erster, Ph.D., Jo Southern, Ph.D., Kaijie Pan, M.S., Gabriel Mircus, Ph.D., Marc Lipsitch, D.Phil., Eric J. Haas, M.D., Luis Jodar, Ph.D., Yeheskel Levy, M.D., Sharon Alroy-Preis, M.D.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2021-12-01
Colecção:	EClinicalMedicine
Assuntos:	COVID-19 SARS-CoV-2 vaccine effectiveness prevention mRNA vaccines variant Beta (B.1.351)
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589537021004715
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!